Riluzole and motor neurone disease

Practical Neurology

Volumn 3, Issue 3, 2003, Pages 160-169

  Turner, Martin R ^a   Al Chalabi, Ammar ^a   Shaw, Christopher E ^a   Leigh, P Nigel ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIAZOLE; PLACEBO; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTHENIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; LIVER DYSFUNCTION; META ANALYSIS; MOTOR NEURON DISEASE; NAUSEA; QUALITY OF LIFE; RETROSPECTIVE STUDY;

EID: 0043172609     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1474-7766.2003.07145.x     Document Type: Article

References (39)

1. Armon C, Guiloff RJ & Bedlack R (2002) Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders, 3, 109-12.
2. Arriada-Mendicoa N, Otero-Siliceo E, Burbano G & Corona-Vazquez T (1999) Open label study of riluzole for the treatment of amyotrophic lateral sclerosis. Revista Ecuatoriana de Neurologia, 8, 33-6.
3. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P & Meininger V (2002) A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. Journal of Neurology, 249, 609-15.
4. Bensimon G, Lacomblez L & Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group [see comments]. New England Journal of Medicine, 330, 585-91.
5. Booth-Clibborn N, Best L & Stein K (1997) Riluzole for motor neurone disease. In: Development and Evaluation Committee Report (eds Best L, Milne R & Stein K), pp 1-21. The Wessex Institute for Health Research and Development, Southampton, UK.
6. Brooks BR, Belden DS & Roelke K et al. (2001) Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) /motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiologic study. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders, 2 (Suppl), 60-61.
7. Chilcott J, Golightly P, Jefferson D, McCabe CJ & Walters S (1997) The use of riluzole in the treatment of amyotrophic lateral sclerosis (motor neurone disease), pp. 1-37. Trent Institute for Health Services Research, University of Leicester, Nottingham and Sheffield, Sheffield.
8. Chio A, Mora G, Leone M et al. (2002) Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology, 59, 99-103.
9. Couratier P, Druet-Cabanac M, Truong CT et al. (2000) [Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS]. Revue Neurologique (Paris), 156, 357-63.
10. Desiato MT, Palmieri MG, Giacomini P, Scalise A, Arciprete F & Caramia MD (1999) The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation. Journal of Neurological Science, 169, 98-107.
11. Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology, 47, S233-S241.
12. Doble A (1999) The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacological Therapy, 81, 163-221.
13. Ginsberg GM & Lev B (1997) Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis. Pharmacoeconomics, 12, 578-84.
14. Gray AM (1998) ALS/MND and the perspective of health economics. Journal of Neurological Science, 160, S2-S5.
15. Guiloff RJ, Goonetilleke A & Emami J (1996) Riluzole and amyotrophic lateral sclerosis. Lancet, 348, 336-7.
16. Kalra S, Cashman NR, Genge A & Arnold DL (1998) Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport, 9, 1757-61.
17. Lacomblez L, Bensimon G, Leigh PN et al. (2002) Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders, 3, 23-9.
18. Lacomblez L, Bensimon G, Leigh PN, Guillet P & Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II [see comments]. Lancet, 347, 1425-31.
19. Meininger V, Lacomblez L & Salachas F (2000) What has changed with riluzole? Journal of Neurology, 246, 19-22.
20. Meininger V & Salachas F (2000) Review of clinical trials. In: Amyotrophic Lateral Sclerosis (eds Meininger V, Swash M, & Brown RH Jr), pp. 389-402. Martin Dunitz, London.
21. Messori A, Trippoli S, Becagli P & Zaccara G (1999) Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO Sui Farmaci Pharmacoeconomics, 16, 153-63.
22. Miller RG, Munsat TL, Swash M & Brooks BR (1999) Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research. Journal of Neurological Science, 169, 2-12.
23. Miller RG, Mitchell JD, Lyon M & Moore DH (2002) Riluzole for amyotrophic lateral sclerosis (ALS) / motor neuron disease (MND) (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. Metalview © Update Software, Oxford.
24. Munsat TM, Riviere M, Swash M & Leclerc C (1998) Economic burden of amyotrophic lateral sclerosis in the United Kingdom. Journal of Medical Economics, 1, 235-45.
25. National Institute of Clinical Excellence (2001) Guidance on the Use of Riluzole (Rilutek) for the Treatment of Motor Neurone Disease. National Institute of Clinical Excellence, London. http://www.nice.org.uk/pdf/RILUZOLE_full_guidance.pdf
26. Non-small Cell Lung Cancer Collaborative Group (2003) Chemotherapy for non-small cell lung cancer (Cochrane Review). The Cochrane Library, 1.
27. Pongratz D, Neundorfer B & Fischer W (2000) German open label trial of riluzole 50 mg B.i.d. in treatment of amyotrophic lateral sclerosis (ALS). Journal of Neurological Science, 180, 82-5.
28. Quality Standards Subcommittee of the American Academy of Neurology (1997) Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 49, 657-9.
29. Riviere M, Meininger V, Zeisser P & Munsat T (1998) An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Archives of Neurology, 55, 526-8.
30. Rosas HD, Koroshetz WJ, Jenkins BG et al. (1999) Riluzole therapy in Huntington's disease (HD). Movement Disorders, 14, 326-30
31. Rowland LP (1994) Riluzole for the treatment of amyotrophic lateral sclerosis - too soon to tell? New England Journal of Medcine, 330, 636-7.
32. Schiefer J, Landwehrmeyer GB, Luesse HG et al. (2002) Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Movement Disorders, 17, 748-57.
33. Sojka P, Andersen PM & Forsgren L (1997) Effects of riluzole on symptom progression in amyotrophic lateral sclerosis. Lancet, 349, 176-7.
34. Tavakoli M & Malek M (2001) The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. Journal of Neurological Science, 191, 95-102.
35. Traynor BJ, Alexander M, Corr B, Frost E & Hardiman O (2003) An outcome study of riluzole in amyotrophic lateral sclerosis. A population-based study in Ireland 1996-2000. Journal of Neurology, 250, 473-9.
36. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN & Al-Chalabi A (2002) Prognostic modeling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders, 3, 15-21.
37. Turner MR, Parton MJ & Leigh PN (2001) Clinical trials in ALS: an overview. Seminars in Neurology, 21, 167-75.
38. Williams VC, Turner MR, Murphy CL et al. (2001) A Retrospective Review of 154 Patients Presenting with Lower Motor Neuron (LMN) Syndromes. Journal of Neurological Science, 187(suppl. 1), S215.
39. Yanagisawa N, Tashirao K, Tohgi H et al. (1997) Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo controlled study in Japan. Igakuno Ayumi, 182, 851-66.